SI-BONE, Inc. (NASDAQ:SIBN) Given Consensus Recommendation of “Buy” by Analysts

Shares of SI-BONE, Inc. (NASDAQ:SIBN) have received a consensus rating of “Buy” from the six analysts that are covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a buy rating. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $23.00.

Several brokerages recently commented on SIBN. Needham & Company LLC reiterated a “buy” rating and set a $19.00 target price on shares of SI-BONE in a report on Wednesday, November 20th. Truist Financial raised their target price on SI-BONE from $16.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday, November 13th.

Insiders Place Their Bets

In other SI-BONE news, CEO Laura Francis sold 10,048 shares of SI-BONE stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $12.58, for a total transaction of $126,403.84. Following the sale, the chief executive officer now directly owns 482,875 shares in the company, valued at $6,074,567.50. The trade was a 2.04 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Anthony J. Recupero sold 3,305 shares of SI-BONE stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $13.58, for a total value of $44,881.90. Following the completion of the transaction, the insider now owns 233,412 shares of the company’s stock, valued at approximately $3,169,734.96. The trade was a 1.40 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 21,679 shares of company stock worth $276,439 in the last three months. 3.90% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Franklin Resources Inc. boosted its position in SI-BONE by 9.4% during the 3rd quarter. Franklin Resources Inc. now owns 20,220 shares of the company’s stock valued at $265,000 after purchasing an additional 1,745 shares during the period. Barclays PLC boosted its position in SI-BONE by 190.8% during the 3rd quarter. Barclays PLC now owns 96,623 shares of the company’s stock valued at $1,350,000 after purchasing an additional 63,402 shares during the period. Geode Capital Management LLC boosted its position in SI-BONE by 3.4% during the 3rd quarter. Geode Capital Management LLC now owns 924,044 shares of the company’s stock valued at $12,921,000 after purchasing an additional 30,005 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in SI-BONE during the 3rd quarter valued at approximately $448,000. Finally, Pier Capital LLC boosted its position in SI-BONE by 23.6% during the 3rd quarter. Pier Capital LLC now owns 465,898 shares of the company’s stock valued at $6,513,000 after purchasing an additional 88,897 shares during the period. Institutional investors and hedge funds own 98.11% of the company’s stock.

SI-BONE Stock Performance

SI-BONE stock opened at $13.84 on Wednesday. The stock’s 50-day moving average is $13.40 and its 200-day moving average is $14.10. The company has a market cap of $580.42 million, a price-to-earnings ratio of -15.04 and a beta of 1.20. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. SI-BONE has a 12 month low of $11.70 and a 12 month high of $21.70.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.